Partial normalization of components of metabolic syndrome does not influence prevalent echocardiographic abnormalities: The HyperGEN study

G. de Simone, D. K. Arnett, M. Chinali, M. De Marco, D. C. Rao, A. T. Kraja, Steven Hunt, R. B. Devereux

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background and aims: Metabolic syndrome (MetS) is a complex condition characterized by different phenotypes, according to the combinations of risk factors and is associated with cardiovascular abnormalities. Whether control of MetS components by treatment produces improvement in the associated cardiovascular abnormalities is unknown. We investigated whether partial control of components of MetS was associated with less echocardiographic abnormalities than the complete presentation of MetS based on measured components. Methods and results: We evaluated markers of echocardiographic preclinical cardiovascular disease in MetS (ATP III) defined by measured components or by history of treatment, in 1421 African-American and 1195 Caucasian non-diabetic HyperGEN participants, without prevalent cardiovascular disease or serum creatinine >2 mg/dL. Of 2616 subjects, 512 subjects had MetS by measured components and 328 by history. Hypertension was found in 16% of participants without MetS, 6% of those with MetS by history and 42% of those with MetS by measured components. Obesity and central fat distribution had similar prevalence in both MetS groups (both p < 0.0001 vs. No-MetS). Blood pressure was similar in MetS by history and No-MetS, and lower than in MetS by measured components (p < 0.0001). LV mass and midwall shortening, left atrial (LA) dimension and LA systolic force were similarly abnormal in both MetS groups (all p < 0.0001 vs. No-MetS) without difference between them. Conclusions: There is a little impact of control by treatment of single components of MetS (namely hypertension) on echocardiographic abnormalities. Lower blood pressure in participants with MetS by history was not associated with substantially reduced alterations in cardiac geometry and function.

Original languageEnglish
Pages (from-to)38-45
Number of pages8
JournalNutrition, Metabolism and Cardiovascular Diseases
Volume23
Issue number1
DOIs
Publication statusPublished - Jan 2013
Externally publishedYes

Fingerprint

History
Cardiovascular Abnormalities
Cardiovascular Diseases
Blood Pressure
Hypertension
Abdominal Obesity
African Americans
Creatinine
Therapeutics
Adenosine Triphosphate
Fats
Phenotype
Serum

Keywords

  • Cardiovascular risk
  • High blood pressure
  • Hypertension
  • Hypertrophy
  • Metabolic syndrome
  • Obesity
  • Risk factors

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Nutrition and Dietetics
  • Endocrinology, Diabetes and Metabolism
  • Cardiology and Cardiovascular Medicine

Cite this

Partial normalization of components of metabolic syndrome does not influence prevalent echocardiographic abnormalities : The HyperGEN study. / de Simone, G.; Arnett, D. K.; Chinali, M.; De Marco, M.; Rao, D. C.; Kraja, A. T.; Hunt, Steven; Devereux, R. B.

In: Nutrition, Metabolism and Cardiovascular Diseases, Vol. 23, No. 1, 01.2013, p. 38-45.

Research output: Contribution to journalArticle

de Simone, G. ; Arnett, D. K. ; Chinali, M. ; De Marco, M. ; Rao, D. C. ; Kraja, A. T. ; Hunt, Steven ; Devereux, R. B. / Partial normalization of components of metabolic syndrome does not influence prevalent echocardiographic abnormalities : The HyperGEN study. In: Nutrition, Metabolism and Cardiovascular Diseases. 2013 ; Vol. 23, No. 1. pp. 38-45.
@article{04871434cb9c4e44823026eeb9c28ca3,
title = "Partial normalization of components of metabolic syndrome does not influence prevalent echocardiographic abnormalities: The HyperGEN study",
abstract = "Background and aims: Metabolic syndrome (MetS) is a complex condition characterized by different phenotypes, according to the combinations of risk factors and is associated with cardiovascular abnormalities. Whether control of MetS components by treatment produces improvement in the associated cardiovascular abnormalities is unknown. We investigated whether partial control of components of MetS was associated with less echocardiographic abnormalities than the complete presentation of MetS based on measured components. Methods and results: We evaluated markers of echocardiographic preclinical cardiovascular disease in MetS (ATP III) defined by measured components or by history of treatment, in 1421 African-American and 1195 Caucasian non-diabetic HyperGEN participants, without prevalent cardiovascular disease or serum creatinine >2 mg/dL. Of 2616 subjects, 512 subjects had MetS by measured components and 328 by history. Hypertension was found in 16{\%} of participants without MetS, 6{\%} of those with MetS by history and 42{\%} of those with MetS by measured components. Obesity and central fat distribution had similar prevalence in both MetS groups (both p < 0.0001 vs. No-MetS). Blood pressure was similar in MetS by history and No-MetS, and lower than in MetS by measured components (p < 0.0001). LV mass and midwall shortening, left atrial (LA) dimension and LA systolic force were similarly abnormal in both MetS groups (all p < 0.0001 vs. No-MetS) without difference between them. Conclusions: There is a little impact of control by treatment of single components of MetS (namely hypertension) on echocardiographic abnormalities. Lower blood pressure in participants with MetS by history was not associated with substantially reduced alterations in cardiac geometry and function.",
keywords = "Cardiovascular risk, High blood pressure, Hypertension, Hypertrophy, Metabolic syndrome, Obesity, Risk factors",
author = "{de Simone}, G. and Arnett, {D. K.} and M. Chinali and {De Marco}, M. and Rao, {D. C.} and Kraja, {A. T.} and Steven Hunt and Devereux, {R. B.}",
year = "2013",
month = "1",
doi = "10.1016/j.numecd.2011.02.004",
language = "English",
volume = "23",
pages = "38--45",
journal = "Nutrition, Metabolism and Cardiovascular Diseases",
issn = "0939-4753",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Partial normalization of components of metabolic syndrome does not influence prevalent echocardiographic abnormalities

T2 - The HyperGEN study

AU - de Simone, G.

AU - Arnett, D. K.

AU - Chinali, M.

AU - De Marco, M.

AU - Rao, D. C.

AU - Kraja, A. T.

AU - Hunt, Steven

AU - Devereux, R. B.

PY - 2013/1

Y1 - 2013/1

N2 - Background and aims: Metabolic syndrome (MetS) is a complex condition characterized by different phenotypes, according to the combinations of risk factors and is associated with cardiovascular abnormalities. Whether control of MetS components by treatment produces improvement in the associated cardiovascular abnormalities is unknown. We investigated whether partial control of components of MetS was associated with less echocardiographic abnormalities than the complete presentation of MetS based on measured components. Methods and results: We evaluated markers of echocardiographic preclinical cardiovascular disease in MetS (ATP III) defined by measured components or by history of treatment, in 1421 African-American and 1195 Caucasian non-diabetic HyperGEN participants, without prevalent cardiovascular disease or serum creatinine >2 mg/dL. Of 2616 subjects, 512 subjects had MetS by measured components and 328 by history. Hypertension was found in 16% of participants without MetS, 6% of those with MetS by history and 42% of those with MetS by measured components. Obesity and central fat distribution had similar prevalence in both MetS groups (both p < 0.0001 vs. No-MetS). Blood pressure was similar in MetS by history and No-MetS, and lower than in MetS by measured components (p < 0.0001). LV mass and midwall shortening, left atrial (LA) dimension and LA systolic force were similarly abnormal in both MetS groups (all p < 0.0001 vs. No-MetS) without difference between them. Conclusions: There is a little impact of control by treatment of single components of MetS (namely hypertension) on echocardiographic abnormalities. Lower blood pressure in participants with MetS by history was not associated with substantially reduced alterations in cardiac geometry and function.

AB - Background and aims: Metabolic syndrome (MetS) is a complex condition characterized by different phenotypes, according to the combinations of risk factors and is associated with cardiovascular abnormalities. Whether control of MetS components by treatment produces improvement in the associated cardiovascular abnormalities is unknown. We investigated whether partial control of components of MetS was associated with less echocardiographic abnormalities than the complete presentation of MetS based on measured components. Methods and results: We evaluated markers of echocardiographic preclinical cardiovascular disease in MetS (ATP III) defined by measured components or by history of treatment, in 1421 African-American and 1195 Caucasian non-diabetic HyperGEN participants, without prevalent cardiovascular disease or serum creatinine >2 mg/dL. Of 2616 subjects, 512 subjects had MetS by measured components and 328 by history. Hypertension was found in 16% of participants without MetS, 6% of those with MetS by history and 42% of those with MetS by measured components. Obesity and central fat distribution had similar prevalence in both MetS groups (both p < 0.0001 vs. No-MetS). Blood pressure was similar in MetS by history and No-MetS, and lower than in MetS by measured components (p < 0.0001). LV mass and midwall shortening, left atrial (LA) dimension and LA systolic force were similarly abnormal in both MetS groups (all p < 0.0001 vs. No-MetS) without difference between them. Conclusions: There is a little impact of control by treatment of single components of MetS (namely hypertension) on echocardiographic abnormalities. Lower blood pressure in participants with MetS by history was not associated with substantially reduced alterations in cardiac geometry and function.

KW - Cardiovascular risk

KW - High blood pressure

KW - Hypertension

KW - Hypertrophy

KW - Metabolic syndrome

KW - Obesity

KW - Risk factors

UR - http://www.scopus.com/inward/record.url?scp=84872688390&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872688390&partnerID=8YFLogxK

U2 - 10.1016/j.numecd.2011.02.004

DO - 10.1016/j.numecd.2011.02.004

M3 - Article

C2 - 21570269

AN - SCOPUS:84872688390

VL - 23

SP - 38

EP - 45

JO - Nutrition, Metabolism and Cardiovascular Diseases

JF - Nutrition, Metabolism and Cardiovascular Diseases

SN - 0939-4753

IS - 1

ER -